Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

The recommended dose for Skyrizi is 150 mg – administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and 4. It can be administered in-office or by ...

Baseline Psoriasis Activity Skin Index (PASI) and Physician Global Assessment scores were higher in the induction group, indicative of greater disease severity. The researchers observed ...

Policia nuk bën të qartë dinamikën e sherrit, ndërsa vetë Çipa pretendon se ditën e djeshme ndërsa ecte me automjet në zonën ku po ndërton linjën elektrike i kanë dalë para dy persona dhe i kanë ...

While its blockbuster Humira faces biosimilar competition, the company's newer drugs Rinvoq and Skyrizi are delivering impressive results. Management's combined sales forecast for these ...

While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% on an operational basis, mainly driven by robust sales of its immunology medicines, Skyrizi and Rinvoq. While ...

The company's immunology drugs, Skyrizi and Rinvoq, exceeded sales forecasts by 5% and 8%, respectively, effectively compensating for the 13% decline in Humira sales. This performance underscores ...

posted a fourth quarter revenue beat and raised its long-term sales guidance for new drugs Skyrizi and Rinvoq by $4 billion. BMO Capital Markets managing director Evan Seigerman sits down with ...

The reported number represents a year-over-year change of +3.2%. Net Revenue- Immunology- Skyrizi- International: $466 million versus the five-analyst average estimate of $506.42 million. The reported ...